Source: FDA Commissioner Statement, 2025
Source: FDA FY2025 Inspection Data
Source: GAO-26-107779, February 2026
Editor's Choice: Key FDA Jurisdiction and Enforcement Statistics
July 1 to December 3, 2025. A 73% increase over the same period in FY2024, following the brief enforcement pause at the start of the year. Reed Smith, December 2025
Up from just 5 in FY2024. Untitled letters now represent a first enforcement escalation step rather than a rarely used tool. Reed Smith, December 2025
vs 190 in FY2024 (+59%). September 9, 2025 crackdown issued 60+ letters in a single day. Pharmaceutical Online, March 2026
1. What FDA Regulates: The $3.9 Trillion Jurisdiction
The FDA is one of the most sweeping regulatory agencies in the United States by product scope. Its jurisdiction covers approximately 78 cents of every dollar spent by U.S. consumers, including food and beverages, prescription drugs, biologics, medical devices, dietary supplements, cosmetics, tobacco products, and veterinary products. The GAO’s February 2026 oversight report placed the total value of FDA-regulated products at $3.9 trillion, making it one of the largest regulatory footprints of any federal agency. GAO-26-107779, February 2026
| Product Category | Primary Regulation | Scope Note |
|---|---|---|
| Food and Beverages | FDCA and FSMA | All food for human and animal consumption except meat, poultry, and egg products (USDA jurisdiction). Largest single category by product volume. |
| Prescription Drugs | FDCA (21 CFR 200-299) | All prescription drugs manufactured, imported, or distributed in the U.S. Includes new drug applications (NDAs) and abbreviated new drug applications (ANDAs). |
| Biologics | PHS Act Section 351 | Vaccines, blood products, gene therapies, and most monoclonal antibodies. Regulated by CBER and CDER depending on product type. |
| Medical Devices | FDCA (21 CFR 800-898) | From Band-Aids to implantable cardiac devices. Class I, II, and III risk-based classification system. QMSR effective February 2, 2026. |
| Dietary Supplements | DSHEA (21 CFR 101, 111) | Unlike drugs, supplements are not approved before sale. Manufacturers are responsible for safety. FDA can act after a product is on the market. |
| Cosmetics | MoCRA (effective 2023) | First significant cosmetics legislation since 1938. Requires facility registration, product listing, and adverse event reporting as of 2023-2024. |
| Tobacco Products | TCA (21 CFR 1100-1185) | Authority granted in 2009. Covers cigarettes, smokeless tobacco, e-cigarettes, and cigars. Pre-market authorization required for new tobacco products. |
| Veterinary Products | FDCA (21 CFR 500-599) | Animal drugs, animal food, and animal medical devices. CVM enforces GMP requirements for animal drug manufacturers. |
Source: FDA: What Does FDA Regulate? | GAO-26-107779, February 2026
2. How FDA Enforcement Works: The Escalation Ladder
The escalation from 483 to warning letter is not automatic. FDA evaluates the inspection classification (NAI, VAI, or OAI) after the establishment inspection report is completed. OAI (Official Action Indicated) classifications trigger potential warning letter issuance, while NAI (No Action Indicated) closes the inspection without enforcement consequence.
3. The Three Inspection Classifications: NAI, VAI, OAI
In FY2024, 93% of inspected sites achieved NAI or VAI classification in the pharmaceutical quality dataset. However, that 7% OAI rate against 989 inspections generated the warning letters that represent the most significant enforcement burden for the industry. The concentration of enforcement consequences in a small proportion of inspections means that OAI-classified facilities face an immediate and significant escalation risk. FDA FY2024 State of Pharmaceutical Quality Report
4. Project Elsa: FDA's AI-Driven Inspection Targeting System
Source: FDA Project Elsa announcement, June 2025
The most important operational implication of the Elsa system: FDA’s inspector knows what your compliance data shows before they arrive at your facility. Unresolved CAPAs, adverse event patterns, and documentation inconsistencies are being flagged before the inspection visit, not discovered during it. This fundamentally changes the relationship between a manufacturer’s day-to-day compliance posture and its inspection risk profile. FDA Project Elsa announcement, June 2025
- Open CAPAs and adverse event clusters are visible to FDA before the inspector’s first step on site
- One-day inspections are determined by AI pre-screening, not facility size or inspection history alone
- Import screenings apply Elsa’s risk scoring to 16+ million product lines continuously
- The system is designed to scale across all FDA-regulated industry segments by 2026
5. FY2025 Enforcement by Industry: Drugs, Devices, Food, and Biologics
- 303 drug/biologics warning letters in FY2025 vs 190 in FY2024 (+59%)
- 82 more warning letters than the prior year
- September 9, 2025: advertising crackdown issued 60+ letters in a single day
- 184 citations for 21 CFR 211.22(d) in FY2024 (most-cited for 4 consecutive years)
Pharmaceutical Online, March 2026
- Device-specific quality enforcement letters increased five-fold from 6 in 2021 to 30 in 2025
- QMSR became effective February 2, 2026, harmonising requirements with ISO 13485
- Top three device citation categories in Q1 2026: CAPA deficiencies, complaint handling failures, supplier control gaps
- 30 device enforcement letters in 2025 vs 6 in 2021
Cloudtheapp, June 2026
- MoCRA cosmetics facility registration deadline passed in 2023-2024
- PFAS assessment in food packaging under active GAO review
- Food safety has been on GAO High-Risk List since 2007
- Untitled letters used more frequently for food labeling violations in FY2025
GAO-26-107779, February 2026
- Pre-market authorization requirements for new tobacco products remain active enforcement priority
- E-cigarette and vaping product enforcement expanded in FY2025
- TCA authority has been on GAO High-Risk List since 2009
- FDA continues to deny most PMTA applications for flavored e-cigarettes
FDA Tobacco Enforcement Data, 2025
6. Foreign Site Scrutiny and GAO's Assessment of FDA Capacity
- FDA oversees $3.9 trillion in regulated products with staffing levels the GAO describes as a capacity challenge
- Medical product oversight on High-Risk List since 2009; food safety since 2007
- Unannounced international inspections now apply to Chinese and Indian manufacturers
- Most prior GAO recommendations remain unaddressed as of December 2025
- One-day inspection pilot reduces per-site resource requirement but depends on AI pre-screening accuracy
GAO-26-107779: FDA Oversight Responsibilities and Funding FY2008-FY2024
7. What the Enforcement Data Means for Regulated Entities in 2026
10 Important FDA Jurisdiction and Enforcement Facts
Ten data points from FY2024-2026 FDA jurisdiction and enforcement records that quality, compliance, and regulatory affairs teams need to know.
Drug and biologics warning letters rose from 190 in FY2024 to 303 in FY2025, the largest single-year increase in at least five years.
78 cents of every dollar spent by U.S. consumers falls under FDA jurisdiction, from food and drugs to cosmetics and tobacco.
Total value of products under FDA oversight as of the GAO February 2026 report, the largest regulatory product footprint of any federal agency.
FDA conducted 694 more inspections across all regulated industries in FY2025 compared to FY2024, as the agency cleared its pandemic backlog and expanded operations.
Up from just 5 in FY2024. Untitled letters are now a routine first enforcement step, not a rarely used tool.
62% of all drug quality inspections in FY2024 were at foreign manufacturing sites, an all-time high reflecting FDA’s international oversight expansion.
Project Elsa applies AI risk scoring continuously to more than 16 million product lines in FDA’s import screening system.
FDA medical product oversight has been on GAO’s High-Risk List since 2009. Food safety oversight since 2007. Both remain on the list as of 2026.
Only approximately 7% of FY2024 drug quality inspections resulted in OAI (Official Action Indicated) classification, but that 7% generated the vast majority of warning letters.
= AI READS YOUR FILE FIRST The Most Important Operational Change in FDA Enforcement
Project Elsa processes a manufacturer’s complete compliance history, adverse event reports, and historical 483 observations before an inspector arrives. Compliance posture is now assessed continuously, not only at inspection. An organisation with open CAPAs, adverse event clusters, or documentation inconsistencies is flagged as high-risk before the first inspector step on site. Source: FDA Project Elsa, June 2025
5 Myths About FDA Jurisdiction and Enforcement
A brief enforcement pause means FDA has reduced its enforcement priorities.
The enforcement pause at the start of 2025 was followed by a 73% increase in warning letters in H2 FY2025. 327 warning letters were issued from July to December 2025 alone. The pause accelerated enforcement pressure on organisations that did not use the window to remediate. FDA’s enforcement posture in FY2025 is more intense than FY2024, not less.
Elsa is only relevant to pharmaceutical manufacturers.
Project Elsa is being deployed agency-wide across all FDA-regulated industry segments. In 2025 it was applied to import screening across 16 million product lines. By 2026 it is intended to cover food, devices, biologics, and tobacco enforcement targeting. Any regulated entity with FDA interaction is in scope.
A 93% NAI/VAI rate means FDA enforcement is rarely a serious risk.
The 93% figure describes classification outcomes, not risk exposure. The 7% of inspections resulting in OAI classification generated the 303 drug warning letters in FY2025, consent decrees, import alerts, and injunctions. Enforcement consequences are highly concentrated. A single OAI classification triggers an enforcement cascade that can halt a manufacturer’s U.S. market access.
Foreign manufacturing reduces FDA inspection exposure.
62% of drug quality inspections in FY2024 were at foreign sites, the highest proportion ever recorded. FDA is actively expanding unannounced inspection programmes at Chinese and Indian manufacturing facilities. The assumption that geographic distance from the U.S. reduces inspection risk contradicts the current inspection data.
Untitled letters do not require a formal compliance response.
58 untitled letters were issued in FY2025, up from 5 in FY2024. An untitled letter is a documented signal of compliance deficiency that enters FDA’s enforcement record. Project Elsa factors prior enforcement signals into inspection risk scoring. An unresponded untitled letter is a compliance liability that persists in the data FDA reviews before its next inspection of your facility.
Impact on Regulated Entities
Pre-Inspection AI Exposure
Elsa’s pre-inspection analysis means open CAPAs, adverse event clusters, and documentation inconsistencies are visible to FDA before an inspector arrives. The compliance posture that existed on inspection day is no longer the starting point. The compliance history is.
Warning Letter Escalation Risk
303 drug warning letters in FY2025 is the new enforcement baseline. Organisations that treated the enforcement pause as a signal of reduced scrutiny face elevated risk. The warning letter cohort includes both chronic violators and first-time recipients whose compliance investments were deferred.
Foreign Manufacturer Exposure
With 62% of drug quality inspections at foreign sites and unannounced inspections expanding internationally, the premise that a foreign manufacturing location is a lower-inspection-risk location is no longer supportable from the data. Indian and Chinese manufacturers in particular are experiencing the full force of FDA’s expanded international programme.
AI Documentation Requirements
The April 2, 2026 Purolea warning letter established that AI use in CGMP documentation requires a documented human review and authorisation step before content enters the quality management system. Elsa can identify AI-related documentation inconsistencies before inspection. Organisations using AI in quality documentation without a formal review gate face citation risk under 21 CFR 211.22(c).
How to Respond to the FY2025-2026 FDA Enforcement Environment
Audit Your Compliance Posture Now
Assume Elsa has already seen your adverse event history, open CAPAs, and 483 trend. Conduct an internal audit against the same data FDA is reviewing before your next inspection.
Close Open CAPAs Before Inspection
Open CAPAs are the most visible compliance signal in pre-inspection AI screening. Any unresolved corrective action is a documented risk flag. Close or formally justify every open CAPA on your register.
Treat Foreign Sites as Equal Inspection Risk
Apply the same compliance investment to foreign manufacturing sites as domestic ones. Unannounced inspections are expanding. 62% of drug inspections are already at foreign sites.
Respond to Untitled Letters Formally
An untitled letter in FY2025 is not a minor communication. Respond formally, document your corrective actions, and treat it as an enforcement signal that will appear in Elsa’s pre-inspection risk scoring for your next inspection.
Establish an AI Documentation Review Gate
Any AI-generated content entering controlled quality documents requires a documented human review and authorisation step. The Purolea warning letter cited 21 CFR 211.22(c). Establish the gate before the next inspection.
Use the Current Enforcement Baseline for Planning
FY2025 warning letter volumes (303 drug, 30 device) are the planning baseline, not an anomaly. Compliance budgets, remediation timelines, and risk assessments should be built against the FY2025 enforcement environment, not FY2024.
Key Takeaways for Regulated Entities and Quality Teams
Sources
Government and Regulatory Sources
- GAO-26-107779 (February 2026): FDA: Oversight Responsibilities and Funding FY2008-FY2024: $3.9T regulated products figure, High-Risk List status, staffing capacity challenges, and December 2025 recommendation status.
- FDA FY2024 State of Pharmaceutical Quality Report: 989 drug quality inspections, 62% foreign site rate, NAI/VAI classification data.
- FDA: What Does FDA Regulate?: 78 cent of every U.S. consumer dollar jurisdiction scope.
- FDA Project Elsa Announcement, June 2, 2025: Elsa system capabilities, import screening scope, one-day inspection pilot details.
- FDA Purolea Warning Letter, April 2, 2026: First warning letter citing AI use in CGMP documentation; citations under 21 CFR 211.22(c).
- FDA Tobacco Enforcement Actions, 2025: Tobacco and e-cigarette enforcement priorities.
Standards and Industry Sources
- Pharmaceutical Online, March 2026: Trends in FDA FY2025 Warning Letters: 303 drug warning letters, 59% increase, September 9 crackdown detail.
- Reed Smith, December 2025: FDA Inspections in 2025: 327 H2 FY2025 warning letters, 73% increase, untitled letter data, one-day inspection pilot.
- Cloudtheapp, June 2026: FDA Enforcement Trends Q1 2026: Device enforcement five-fold increase, QMSR transition context, CAPA and complaint handling top citations.
- Certainty Software, 2026: FDA Warning Letters and Quality System Failures: 211.22(d) citation count, four-year citation pattern analysis.
Research Sources
- GMP Insiders, February 2026: FY2025 FDA Inspection Observations: FY2025 inspection observation trends and four-year citation pattern.
- qBench, May 2026: Inside 470 FDA Warning Letters from 2025: Laboratory warning letter analysis across 470 letters in the 2025 dataset.
Related VelSafe Insights
FDA 483 Observations: FY2024-2025 Enforcement Statistics
303 drug warning letters, 184 citations for 21 CFR 211.22(d), and the Purolea AI warning letter. Full enforcement statistics with analysis.
Browse All VelSafe Insights
Evidence-based analysis of FDA enforcement, OSHA citation trends, and regulatory compliance data for quality and compliance professionals.
